文献速递关节外科

全膝关节置换术中静脉与局部地塞米松的比较:随机双盲对照研究

Comparison of Intravenous and Topical Dexamethasone for Total Knee Arthroplasty: A Randomized Double-Blinded Controlled Study of Effects on Dexamethasone Administration Route and Enhanced Recovery.
PubMed 文献 · J Arthroplasty · 2020-11-17

这项双盲安慰剂对照试验将90例初次全膝关节置换患者随机分为静脉地塞米松组和局部地塞米松组,比较两种给药途径的临床效果。局部给药在术后早期静息和活动疼痛评分及膝关节肿胀方面更优,而静脉给药在降低炎症生物标志物和预防术后恶心方面更有效。两组在膝关节活动度、KSS、住院时间和并发症方面无显著差异。

要点

  • 局部地塞米松在TKA术后早期镇痛和减轻肿胀方面优于静脉给药。
  • 静脉地塞米松在降低CRP、IL-6和预防术后恶心方面更有效。
  • 两种给药途径在膝关节功能、住院时间和并发症方面无显著差异。

核心结论

  • 局部地塞米松在TKA术后早期疼痛管理和膝关节肿胀方面提供更好的临床结局。
  • 静脉地塞米松在降低血液炎症生物标志物和预防术后恶心方面更有效。

研究设计与样本

  • 双盲、安慰剂对照随机试验,纳入90例初次全膝关节置换患者。
  • 随机分为静脉地塞米松组(n=45)或局部地塞米松组(n=45,地塞米松加入麻醉鸡尾酒用于关节周围注射)。

主要发现

  • 局部地塞米松组在术后2h、8h、12h静息疼痛评分更低(P < .05)。
  • 局部地塞米松组在术后12h、24h活动疼痛评分更低(P < .05)。
  • 局部地塞米松组术后第一天膝关节肿胀更轻(P < .05)。
  • 静脉地塞米松组术后24h CRP更低(P < .05),术后24h、48h IL-6更低(P < .05)。
  • 静脉地塞米松组术后恶心更少(P < .05)。

关键数值与推荐

  • 主要结局为术后VAS疼痛评分和吗啡消耗量。
  • 次要结局包括膝关节肿胀、屈伸角度、KSS和术后住院时间。
  • 三级结局评估血液指标,包括炎症生物标志物和纤溶参数。
  • 两组在膝关节屈伸角度、KSS、术后住院时间和并发症发生率方面无显著差异(P > .05)。

临床怎么用

  • 可根据临床侧重点选择地塞米松给药途径:局部给药利于早期镇痛和减轻肿胀,静脉给药利于控制炎症和预防恶心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal route for dexamethasone (DEX) administration regimen for patients undergoing primary TKA has not been investigated. This study aims to determine whether intravenous and topical DEX provide different clinical effects in patients with TKA. METHODS: In this double-blinded, placebo-controlled trial, 90 patients undergoing primary TKA were randomized to intravenous DEX group (n = 45) or topical DEX group (n = 45, DEX applied in anesthetic cocktail for periarticular injection). The primary outcome was postoperative VAS pain score and morphine consumption. Secondary outcomes were included knee swelling, knee flexion, and extension angle, Knee Society Score (KSS), and postoperative hospital stays. Tertiary outcomes assessed the blood-related metrics, including inflammatory biomarkers and fibrinolysis parameters. Finally, nausea and vomiting and other adverse events were compared. RESULTS: The topical administration of DEX provide lower pain score at 2h, 8h, 12h at rest (P < .05) and 12h, 24h with activity (P < .05), and less knee swelling in the first postoperative day (P < .05), while intravenous DEX was more effective in decreasing blood inflammatory biomarkers, including C-reactive protein (CRP) at postoperative 24h (P < .05) and interleukin-6 (IL-6) at postoperative 24h, 48h (P < .05), and reducing postoperative nausea (P < .05) for patients receiving TKA. However, there was no significant difference in knee flexion and extension angle, KSS, postoperative hospital stays, and complications occurrence (P > .05) between intravenous and topical DEX after TKA. CONCLUSION: Topical administration of DEX provided better clinical outcomes on postoperative pain management and knee swelling early after TKA, while intravenous DEX was more effective in decreasing blood inflammatory biomarkers and preventing postoperative nausea.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Li D, Wang Q, Zhao X, et al. Comparison of Intravenous and Topical Dexamethasone for Total Knee Arthroplasty: A Randomized Double-Blinded Controlled Study of Effects on Dexamethasone Administration Route and Enhanced Recovery. J Arthroplasty. 2020. PMID: 33293172. doi:10.1016/j.arth.2020.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。